Gaming - Visitors Are Back, and Yields Are Attractive; O/W
Date: 2022-07-14
Firm: RHB-OSK
Stock: GENTING
Price Target: 6.37
Price Call: BUY
Last Price: 4.50
Upside/Downside:
+1.87 (41.56%)
OVERWEIGHT.

At Resorts World Genting (RWG), tourists and gamblers are back, which should fuel a meaningful sector earnings recovery in the coming quarters. While we think that gaming and non-gaming revenues, and number forecast operators’ (NFO) ticket sales should continue recovering towards pre-pandemic levels, we highlight that inflation may dampen consumers’ discretionary spending. Nevertheless, the casinos’ undemanding valuations of 6-8x FY23F EV/EBITDA and NFOs’ attractive yields of c.7% provide a defensive proposition amidst market uncertainty.

The return of tourists and gamblers. From our recent ground checks at RWG on a Wednesday afternoon, we found that hotel rooms are fully booked for the weekends. We were also pleasantly surprised by the large casino crowd on a Wednesday afternoon. As Malaysia’s and Singapore’s borders have reopened, we think that RWG and Resorts World Sentosa (RWS) are likely ramping up efforts to attract tourists from the region.

The casinos are beneficiaries of a weakening MYR, in our view. YTD, the USD has strengthened by c.6% against the MYR. With Genting Malaysia (GENM) typically earning 8-16% of its adjusted EBITDA from the US division (1Q22: 19%), and Genting (GENT) typically earning 6-10% of its adjusted EBITDA from the US (trailing 12-month average: 31%, 1Q22: 21%), the strengthening USD/MYR should translate into higher MYR earnings. As GENT's management is still ramping up the business at Resorts World Las Vegas (RWLV), its EBITDA contribution from the US should rise accordingly. A weaker MYR may also make Malaysia a more affordable tourist destination for foreign tourists, but we note that, historically, more than 80% of RWG's visitors are domestic tourists.

Inflation casts a shadow. May's inflation in most of GENT and GENM's operating markets – Malaysia (2.8%), the US (8.6%), the UK (9.1%), Singapore (5.6%) – have been higher than expected. Given the discretionary nature of casino and leisure spending, we think that potentially persistent and high inflation rates and, as such, weakened consumer spending power, could adversely impact GENM's gaming and non-gaming revenues, as well as GENT's leisure and hospitality businesses.

NFOs – slow recovery, but attractive yields. We gathered that ticket sales in 2Q22 were still at 70-80% of pre-pandemic levels – a sign of punters’ continued weakened financial conditions and reliance on illegal operators. While we think that inflation may drag on ticket sales, we highlight that Magnum offers a dividend yield of 6.7%, and Sports Toto (SPTOTO) offers 7.2%, which we think are attractive amidst market uncertainty.

Top Pick: GENT. GENT’s leisure and hospitality businesses should continue to recover with the on-going resumption in tourism activity. Its plantations and oil & gas units stand to benefit from elevated ASPs stemming from high commodity prices. Its 6.3x FY23F EV/EBITDA is attractive vs the regional peer average of 12x, and any additional value accretion from GENT’s 20%-owned TauRx Pharmaceuticals is a plus point. Among the NFOs, we prefer SPTOTO. Apart from its continued ticket sales recovery, we also like the growth exposure from its other segments, such as its UK motor dealership and hotel & gaming businesses in Berjaya Philippines. Key risks to the sector include a fluctuation in luck factor, changes in government policies, and a prolonged pandemic.

Source: RHB Securities Research - 14 Jul 2022

https://www.marketwatch.com/story/biogen-stops-clinical-trial-tracking-aduhelm-2022-06-24?siteid=yhoof2

https://finance.yahoo.com/news/athira-pharma-shares-fall-52-122145899.html

https://www.fiercepharma.com/pharma/bms-pfizer-merck-face-extreme-patent-exposure-all-have-financial-flexibility-ma-scores

A few weeks ago, TauRx attended the 35th Alzheimer Disease International Conference held at the Oval in London. With over 1,200 delegates at the 2022 conference, TauRx was proud to support the event as platinum sponsor.

With delegates from over 100 countries, this conference was a prime opportunity to reinforce the importance of tau as a target when developing a potential treatment for Alzheimer’s and to share the latest research from TauRx.

TauRx shared some preliminary information about its LUCIDITY study and welcomed the encouragement from panel members, of the symposium session. The panel discussion was chaired by Professor Serge Gauthier, with engaging discussion from Ms Paola Barbarino, ADI CEO, Dr Richard Stefanacci, Chief Medical Director Eversana and Dr Jefferey Cummings, University of Nevada, Research Professor of Brain Science.

Huge unmet need

Noted during the symposium was the fact LUCIDITY is one of the few trials which targets the tau pathology of Alzheimer’s.

Over 35 million people live with Alzheimer’s disease and many more have mild cognitive impairment and pre-clinical Alzheimer’s. By 2050, 135 million will have Alzheimer’s, it is a huge unmet medical need.

However, it was clear through the varied presentations, posters, and exhibition booths at ADI2022, that we must strive to include people living with dementia in corporate and research activities.

A voice must be given to people most affected by dementia, but we must also collectively strive to focus on education and diagnosis to irradicate the barriers to a timely diagnosis. This includes, as Kielan Arblaster from Alzheimer’s Society highlighted, the need to raise awareness of the value of a diagnosis and greater involvement of primary care providers.

Battling stigma

Throughout, a core theme of the wider conference was raising awareness of dementia to battle the stigma associated with the condition.

A universal agreement at the conference is that dementia doesn’t discriminate, and this is a huge unmet medical need. We must all work together to promote dementia awareness, within society and within our governments to ensure we build a stigma-free culture which encourages individuals to seek out a diagnosis and any support they need free from worry or fear.

A wide range of international case studies were presented to help outline the stages of dementia and Alzheimer’s care and policies in countries around the world. It was great to see examples of how together we can collectively raise awareness.

Fireside Chat

TauRx’s second session was a fireside chat with Dr Sonya Miller, Head of Medical Affairs and Medical Oversight Lead, and Dr Emer MacSweeney, CEO and Head of Re:Cognition Health, one of the largest providers of clinical trials in the UK for neurodegenerative conditions. Joining them were special guests Stanley, who lives with Alzheimer’s, and his son Martin.

Stanley took part in an early clinical trial and now continues to take the investigative medication as part of an extended access program. Initially overwhelmed by his father’s diagnosis, Martin explained he actively searched Google for information on what they could do and discovered clinical trials. Listening to the shared experience of Stanley taking part in a clinical trial with the support from an experienced clinician in the field was overwhelmingly positive.

Old cha cha aunty's posts also have dementia. Can suddenly disappear and forgotten also.

She forgot she started abusive posting first today. Now accusing others of abusive posts. So shameless.

Posted by WinSSP > 35 minutes ago | Report Abuse

enough la… kaki boodek 1invest1
-------------------------------------------------------

Posted by WinSSP > 3 minutes ago | Report Abuse

Posted by AngTayKor> 15 minutes ago | Report Abuse

Agree @MM….
---------------------------------------------------

Aiyo, there is a loser here can even be kaki bodek with dream maker. Most useless and shameless here. HaHa!
——————/-///———————

Ai yo….Makcik ATK….Please stop using abusive language in this public forum!


-----------------------------------------------------------------------------------------------


Who started abusive behaviour first today? Check the record just 35 min ago. Confirm you have dementia. Haha!

Posted by WinSSP > 5 minutes ago | Report Abuse

Posted by AngTayKor > 5 days ago | Report Abuse
------------------------------

Aiyo, there is a loser here can even be kaki bodek with dream maker. Most useless and shameless here. HaHa!



----------------------------------------------------------------

Can even cut and paste my post 6 mins ago (11 min - 5 min) and forgot to type in her own post. Very serious dementia la old cha cha aunty. You need me to help you enroll into Taurx compassionate program?

Posted by WinSSP > 1 minute ago | Report Abuse

Apasal quote 5 days ago Makcik ATK? Basi la :p
--------------------------------------------------

You forgot you have dementia? What is your average entry price now? :)

Posted by WinSSP > 5 days ago | Report Abuse

Agree @MM….
---------------------------------------------------

Aiyo, there is a loser here can even be kaki bodek with dream maker. Most useless and shameless here. HaHa!

Posted by Keyman188 > 1 hour ago | Report Abuse

Amboi...what is happening now !!!...

Keyman188 still maintaining to see KLCI @ 13xx for this year (2022)...

wkwkwk...kekeke...hehehe...
--------------------------------------------------

Aiyo Amboi oldman your "see you at KLCI 13XX soon" prediction was wrong a few months back. KLCI shot up to 16XX, GenB shot up to 5.34. A lot of fellow Genting comrades huat and sold off already, now slowly getting back in.

Of course eventually KLCI will see 13XX. Bear market mah. A dead clock is also correct twice a day right? BTW it seems that "outside window" performing even worse relative to KLCI. Unless you have the foresight to short the "outside window" market..... but you have been encouraging people here to buy the "outside window" market.

Posted by WinSSP > 15 minutes ago | Report Abuse

You are right @MoneyM. ATK Osstrich likes to entertain us. Thanks for the good laughs kikiki
------------------------------------------------------

Dementia old aunty LoserSSP, you forgot that you have been the real clown here? Ostrich also dont know how to spell? You parrot or what? Quickly go and hide your ostrich head in sand la.

So what is your average entry price now? Hahaha....

Posted by MoneyMakers > 5 minutes ago | Report Abuse

Better dont do anything 2 upset AngTK

Last time when proved him wrong, myself got banned 1week for inflicting public humiliation & challenging his intelligence

Really bitter person kikiki
-------------------------------------------------

You are lucky the GenB legal team not going after you for a lot of your rubbish posts here. Next time you spread false rumors again, maybe some Genting comrades will email to GenB and report you. Ask your best friend STOCKSAFEPLAYER why she has to change her name to LoserSSP? I remember some glovers complain to glove companies abt her false rubbish posts here and there should be some pending legal cases against her. Old cha cha aunty is really nuts, in Genting forum can talk so much rubbish abt gloves.

Last fed meeting Powell already said 0.75% not in consideration. But he may give some hawkish projections etc. Fed cannot be fully responsible for high inflation, yet cannot crash the economy. How to control Putin to stop the war? How to stop all the sanctions against Putin? How to tell China dont lockdown it will worsen supply chain disruption? There is real supply shortage, no choice. Alternatively can hike the rates more, bankrupt the highly in debt USA, crash the economy to tame down the demand side. But this method going to end up worse.

Whether its 8.3% to 8.6% or 8.6% to 8.3%, it is still high inflation. Wait until 2023 Feb CPI data then the rate will auto drop because we are comparing CPI to the high base from Putin war Feb 2022 onwards. After 14 years of easy monetary policies by all the global central banks, Im surprise 2022 then inflation really starts to bite hard. We better be mentally prepared and get used to inflation going forward.

Posted by WinSSP > 1 hour ago | Report Abuse

Totally agree with @MM on that 1bodek1…. non-stop yappings banyak until now tapi kosong substance. ATK Ostrich is better, she made the effort to substantiate her comments based on old news
--------------------------------------------------

Can some kind soul here please email and report LoserSSP for her abusive posts? feedback@i3investor.com

Posted by anthonytkh > 42 minutes ago | Report Abuse

“All will fail their phase 3 trials”….. oh, ok Ang….
-------------------------------------------------------

Big names that have failed and / or repeatly failed in disease modifying AD phase 3 trials include Pfizer, JNJ, Eli Lilly, BMS, Roche, Biogen, etc

A lot of small but NASDAQ listed biotechs formerly in hype eventually won't work also. Axovant Science (now known as Sio Gene), Annovis, Cassava, Cortexyme, MC Immune, etc.

An effective disease modifying AD drug is so difficult to develop that even Pfizer gave up and shut down their AD research department a few years ago. Pfizer JV Eisai were the first to commercialise an AD drug called Aricept (now known as Donepezil as a generic drug).

Posted by MoneyMakers > 3 minutes ago | Report Abuse

Looks like AngTK still angry with me after humiliating him few months back

Talk like know everything but actually know nothing 1..apparently proving AngTK wrong he consider ‘personal public humiliation’ kikiki
---------------------------------------------------------

Aiyo failed contra punter dream makers dont come here and spell GERM as GEM abt yourself. When you heng heng didnt lose on your contra punting trades, how many % can you make?

LKT and ATK both have the astute investment skills and good foresight to bet big on Taurx. Chances of phase 3 trial success is 0.1% vs 99.9% and we can bet super big on the correct dark horse... its really not simple. Wake up la dream makers. We are talking abt 100 baggers return eventually.

Posted by anthonytkh > 26 minutes ago | Report Abuse

Ang, let’s just wait and see. I’m a Malaysian and of course I’d like a Malaysian company be involved in a successful treatment for AD (even if the Malaysian company is most famous for a “leisure drug” that have caused suicides)

Glaxo backs another company. There are 3 others currently in Ph2 trials. I think 2 of them are listed in Nasdaq
-----------------------------------------------------------------

All will fail their phase 3 trials. Spreading of misfolded Tau is the root and cause of AD. Even if competitors have some early stage of Tau research program, very difficult to be successful. The correct method is T.A.I = Tau Aggregate Inhibitor. There are good Tau which is essential for the functioning of brain. Some programs targeting the wrong tau, some using wrong method of application. Numerous Tau programs that has already failed. Not so simple. Lucidity's success is a cumulation of 35 years discovery, knowledge and extensive research.

Posted by WinSSP > 3 minutes ago | Report Abuse

Totally agree with @MM on that 1bodek1…. yappings banyak tapi kosong substance. ATK is better, she made the effort to substantiate her comments based on old news :p
--------------------------------------------------------

Old cha cha aunty can team up with dream maker and amboi oldman. Useless and shameless. Everybody also know you have the lowest character here la LoserSSP STOCKSAFEPLAYER.. Go and bury your head inside sand like what ostrich will do ok? Don't be a public joke here. Hahaha..

Posted by WinSSP > 42 minutes ago | Report Abuse

News directly from GB more reliable….
----------------------------------------------------------


These "news" are definitely not reliable. Kekeke......


Posted by Stocksafeplayer > Mar 19, 2021 4:25 PM | Report Abuse
Congrats.......
My average is 4.50....Super grateful aldy!!
-------------------------------
Posted by Stocksafeplayer > Apr 21, 2021 5:45 PM | Report Abuse
My average is 4.20....4.68 too expensive la
-------------------------------
Posted by Stocksafeplayer > Sep 1, 2021 4:31 PM | Report Abuse
Average 4.00…. at 5.05… already more than 250k profit on paper… heng ahh!
--------------------------------
Posted by shareinvestor888 > Jan 27, 2022 6:39 PM | Report Abuse
I bought GenB at 3.50…. Very happy….

MR TAN KONG HAN (a company director) acquired 73,000 shares at 4.730 on 30-May-2022.
MR TAN KONG HAN (a company director) acquired 27,000 shares at 4.680 on 30-May-2022.
--------------------------------------------------------------

This guy is Taurx director also. He must be confident of Taurx.

Posted by newbie2019 > 38 seconds ago | Report Abuse

ATK Sifu when are u entering? or what price will Sifu be entering?
----------------------------------------------------------------


I cannot say too much. Lone wolf trading style quietly come quietly go. FOMC starts tonight and I expect shorts to cover.

Current price is as if Lucidity trial failed. But I know the primary endpoints ADAS-COG = No Decline, ADCS-ADL= 67% slowdown.

Anyone can guess and tell me the valuation of Taurx?

Posted by Income > 27 minutes ago | Report Abuse

Oppa Gangnam style
---------------------------------------

GenB is a Cha Cha stock!

No need to wait for end of 12 month open label for approval submission. The main focus regulators look at is on the first 12 month randomised and blinded phase 3 trial.

No need to wait for drug commercialisation before IPO. Many biotechs in NASDAQ are still not in late stage phase 3 trial, let alone commercialisation stage. Since 99.9% of AD drugs fail at phase 3, Taurx IPO will not be cheap. Investors can buy with certainty with successful phase 3 trial result.

A lot of wrong info articles flying around. Could be planted by whales. Maybank analyst attended ADI conference and reported the following data on HMTM revealed at the conference in London.

Primary Endpint: ADAS-COG = No Decline
Primary Endpoint: ADCS-ADL = 67% slowdown in decline
Secondary Endpoint: Brain atrophy = 50% slowdown in volume shrinkage

Read the trial announcement:
"....participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies."

The report given by Maybank analyst who has attended ADI conference in London is consistent with what Taurx has announced. Not that I want to talk big abt Taurx.... No drugs' performance can surpass or even come anywhere near to HMTM's performance for the next 10 years. This drug is the Holy Grail for all AD patients, caregivers, doctors, govt, etc who have been waiting, praying and hoping for a miracle drug for the past few decades. HMTM will also go into the preventive AD market. Stop the disease before it starts to wreck havoc. Start the treatment early via PET scan for accumulation of toxic Tau tangles biomarkers even before physical AD symptoms appear. Huge existing AD market plus AD preventive market.

Posted by Income > 3 hours ago | Report Abuse

Nobody feels disappointed kah with Taurx results?
The results are so so only. Genting has to wait for another year.

—-
KUALA LUMPUR (March 10): Genting (GENTING, 3182, main board consumer stock) holds 20.3% of the British pharmaceutical company TauRx, in the latest Alzheimer's disease (commonly known as dementia) drug research and development report lack of breakthroughs, leading to the Shares suffered heavy losses today. Genting's share price dropped 34 sen or 6.54% to close at RM4.86 at the open this morning.
-----------------------------------------------------

This type of news need to be careful. Firstly, the date is wrong (March 10). Next, Taurx Pharmaceuticals Ltd is a Singapore company with research facilities in Aberdeen, Scotland. This is officially a 12 month trial, then open label for another 12 more months whereby the placebo patients will also take 16mg active dose after completing the official 12 month trial duration. Taurx do not need another open label extra 12 months to confirm its drug effectiveness for regulatory submissions.

Those untrue rubbish reports abt Taurx flying around on internet could be planted by whales to cause a plunge in share price. As a 0.7% shareholder of Taurx, I know this company for 18 years and they are usually conservative when making their claims.

Read the trial announcement:
"....participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies."

The facts are as above, it is what it is. Just wait for Taurx's official announcement for Lucidity's full trial result even though i heard of some very stunningly positive endpoint measurements data from fellow Taurx investors.

Posted by AngTayKor > 17 hours ago | Report Abuse

Posted by WinSSP > 14 minutes ago | Report Abuse

below 5 better
-------------------------------------

Of course better for professional cha cha dancers. 4 rounds of successful GenB trades this year.

Posted here last night that LKT selling his GenB shares in large volumes daily. Smart traders would have cleared their balance this morning. The dumb fake investor whose average prices can auto drop from 4.50, 4.20, 4.00, 3.50, etc can even give delusional talk abt M&A of GenB at high price.
--------------------------------

Posted by newbie2019 > 21 minutes ago | Report Abuse

ATK sifu sold ur last round last min entrance?
----------------------------------------------------

Too many fake investor's thrash posts here. I have already said I cleared.

Think I better KIV on trading this stock first. If price goes up, insider LKT will start dumping tens of millions shares. Most professional cha cha dancers dislike such scenario. Risk vs reward is not favorable.

Posted by Tobby > 1 day ago | Report Abuse
Bought back Genting this morning at 6.22! Notice the bullish undertone yesterday!
--------------------------------------
Posted by Tobby > 1 day ago | Report Abuse
Hihihaha! Guys! It/s 5.22! Don't blame me! Blame everybody else!
---------------------------------------
Posted by Tobby > 1 day ago | Report Abuse
Fortunately i brought back after seeing the bullish undertone! But this round i only put 20% of my portfolio!
-------------------------------------
Posted by Tobby > 15 minutes ago | Report Abuse
Posted by emsvsi > Jun 10, 2022 12:29 AM | Report Abuse
TOBBY DONT PANIC ON YOUR RM 5.22 SHARES
Answer : Hihihaha! When did i bought at 5.22! Hhhmmm, oh my! I am so forgetful this few days! I wish there's medication for my Alzheimer!
------------------------------------------------------------------

Tobby following that old aunty LoserSSP telling lies also? OK la Tobby's lies still not that bad.... the other fake investor cha cha aunty's lies are much worse.

Aiyo so many fake investors here. Dont come here and cheapen professional cha cha dancer's real trading and investment records la. My 4 out of 4 successful GenB trades this year are real. My 0.7% Taurx shareholdings are real. My arbitrage profits trading Taurx shares are real also. I duno why so many fake investors like to tell lies here.

Posted by WinSSP > 2 hours ago | Report Abuse

Kasihan Aunty Atk….ada dementia, non-stop yapping
--------------------------------------------

Posted by WinSSP > 15 minutes ago | Report Abuse

Aunty Atk Dementia yapping non-stop. Pergi tidur la lol
---------------------------------------------


Dementia cha cha old aunty LoseSSP keep posting and deleting her previous posts. You were yapping non-stop the entire day. I only came in later. You forgot already? Cha cha old aunty's posts also has dementia, miraculously deleted, disappeared and forgotten too.

No time to poke back at fake investor old aunty liow. Watching out for my real investment Taurx's result. Cha cha cha... Jeng Jeng Jeng....

And then LoserSSP will delete away her posts like she didn't post at all. A dementia style of posting, no trace of what she has posted. Kekeke

Aiyo why LoseSSP post already will repost the same thing again at later time? She forgot she posted at earlier time? So fast dementia already?

Posted by WinSSP > 9 seconds ago | Report Abuse

Aunty Atk kasihan ada dementia….
----------------------------------------------------------------

Cha cha aunty LoseSSP what is your average entry price again? Dementia and forget already? ATK help you to recall ok? So funny.... Kikiki....




Posted by Stocksafeplayer > Mar 19, 2021 4:25 PM | Report Abuse

Congrats.......
My average is 4.50....Super grateful aldy!!
-----------------------------

Posted by Stocksafeplayer > Apr 21, 2021 5:45 PM | Report Abuse

My average is 4.20....4.68 too expensive la
----------------------------

Posted by Stocksafeplayer > Sep 1, 2021 4:31 PM | Report Abuse

Average 4.00…. at 5.05… already more than 250k profit on paper… heng ahh!

----------------------------

Posted by shareinvestor888 > Jan 27, 2022 6:39 PM | Report Abuse

I bought GenB at 3.50…. Very happy….

Posted by WinSSP > 3 minutes ago | Report Abuse

When red happens, han tu Aunty Atk appears sampat talk… Hahaha. Thanks for sharing latest news @ETTUSA
--------------------------------------------------

As usual, cha cha aunty always jealous of ATK. See the profile picture? Its a man lah... man become woman... cha cha aunty has both dementia and serious eyesight problems? LoseSSP is also an oldman like Amboi oldman? No wonder birds of same feathers flock together. Kekeke....

I enjoy DJ Tiesto's music.

"Staying Alive", "Staurday Night Fever"... those are baby boomers era of music and movies. Kekeke....

BTW I swear to God and Hell that I am still below fifty years old. Usually teenager or below will call me uncle, thats fine. I never hear before baby boomers calling me uncle. Real become fake, young become old.... Fake become real, old become young..... Only thru the delusional lens and foul mouth of a cha cha aunty. Hahaha.

Posted by WinSSP > 14 minutes ago | Report Abuse

below 5 better
-------------------------------------

Of course better for professional cha cha dancers. 4 rounds of successful GenB trades this year.

Posted here last night that LKT selling his GenB shares in large volumes daily. Smart traders would have cleared their balance this morning. The dumb fake investor whose average prices can auto drop from 4.50, 4.20, 4.00, 3.50, etc can even give delusional talk abt M&A of GenB at high price.

KIEN HUAT INTERNATIONAL LIMITED (a substantial shareholder) disposed 2,692,500 shares on 08-Jun-2022.

KIEN HUAT REALTY SDN BERHAD (a substantial shareholder) disposed 3,026,800 shares on 07-Jun-2022.

KIEN HUAT REALTY SDN BERHAD (a substantial shareholder) disposed 2,357,700 shares on 03-Jun-2022.

KIEN HUAT REALTY SDN BERHAD (a substantial shareholder) disposed 1,200,000 shares on 02-Jun-2022.

KIEN HUAT INTERNATIONAL LIMITED (a substantial shareholder) disposed 20,000,000 shares on 07-Jun-2022.
------------------------------------

OMG what is LKT doing??? Really unexpected!

https://www.asiaone.com/lifestyle/i-want-refund-woman-unhappy-find-closed-rides-and-limited-food-options-uss

Wait... I spotted something strange. Taurx is phrasing the words like this: "decline at a rate substantially less than is typical in Alzheimer’s based on published research."

This statement means that Taurx is comparing their active dose patient's performance in Lucidity trial VS the historical average score for all the placebo patients' for all the previous phase 3 clinical trials done by all other drug companies. I have been attending Taurx's AGMs every year, I have seen this term being used in Taurx's AGM's slides and I am able to comprehend what this announcement statement's phrasing actual meaning.

If Taurx is comparing their active dose's patient performance VS their own trial placebo patient group like in a phase 3 clinical trial scenario, the sentence phrasing should be read as: "decline at a rate substantially less than the trial's placebo patient group."

My personal view is that most likely Lucidity's placebo patient group somehow strangely has a stronger performance when compared to the historical average performance of all the previous phase 3 trials placebo patient group. Lucidity's placebo patient group is receiving the first generation MTC formula in very low dose. This is to make the real active dose pill and the placebo fake pill look and taste exactly the same, including for possible urine discolouration side effects. 18 years ago when I invested in Taurx, private equity investors will joking call this the "Blue Pee Pill". I think there could be some minority cases of minor positive drug effect here even at low dose MTC formula. It is very difficult to formulate a placebo fake pill that looks, taste and pee out in blue like the real pill.

Now I think the real trial result to be announced is going to be below my expected trial result score. This placebo pill become active dose is not a new issue. Taurx experienced this problem before back in 2016 when placebo pill HMTM 4mg was later discovered to be an active dose with powerful drug effects. Because of this placebo pill issue, the entire phase 3 clinical trial failed. I have mentioned abt this before in my earlier post. At that time, Taurx failed to realise that HMTM is actually 60 times the power of MTC formula. They thought its was like 30% more powerful than MTC. Some gross miscalculation then, very painful lesson learned, US$200m trial cost burned just like that, lost 6 years of drug development time.

Posted by Income > 3 hours ago | Report Abuse

I think the results will be middle ground… not too good and not too bad. So Moderate or to be exact 50% efficacy of Taurx. So, Any impact from this 50% efficacy on Genting?

So the most Genting will get out of Taurx is another 20 to 30 sen upside. My 2 sen opinion
------------------------------------------------------

Excellent Lucidity trial results has been largely priced in GentB's share price already. Read the trial announcement:

"....participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies."

Heng got Taurx news to boost up the share price. Without Taurx news, GentB will probably be trading at 4.50 or even back to 4.30 support zone with the shocking Q1 result.

Lucidity Trial has 3 primary end points, 7 secondary end points. Primary endpoints are the most important in any clinical trial. Any primary endpoint fail means non-negotiable trial failure.

Looking at Lucidity's secondary end point item 1-> Rate of decline for brain atrophy. This measurement speaks a lot of volume on drug's performance. AD patients suffer from severe brain shrinkage due to death of brain neurons. Imagine a healthy sea coral's volume vs dried up coral volume. If the brain shrinks at a slower rate, that means brain neurons are dying at a slower rate. The drug is doing its job in slowing down brain neurons death, slowing down disease progression.

https://clinicaltrials.gov/ct2/show/NCT03446001



Here are some of the competitors' phase 3 clinical trial status:

https://www.clinicaltrials.gov/ct2/show/NCT03887455

https://clinicaltrials.gov/ct2/show/NCT04437511

https://www.clinicaltrials.gov/ct2/show/NCT03443973


Do you notice how come all the others are using these newly invented kelong primary endpoints, hopefully the FDA will view their "easier to attain" score more favourably?
-Change from Baseline in the CDR-SB
-Change From Baseline to Week 116 in Global Outcome, as Measured by Clinical Dementia Rating-Sum of Boxes (CDR-SOB)
-Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)

Taurx still still using the traditional gold standard primary endpoint measurement used for the past 20 years. We are the real deal. No need to change into wider kelong goal post.
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
- Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)

Confirm more than 50% for ADAS-COG11 primary endpoint. The other primary endpoint is ADL lifestyle will be lower than cognition score. Very difficult to pass ADL (lifestyl)e. Many new clinical trials shift their goal post to lower standard of endpoint measurements. The traditional style of endpoint measurements, those taurx is using, are the gold label measurement standards. But all the drug manufacturers find it impossible to pass. Hence they using kelong lower standard of measurements.

Slowdown by 90% is effectively almost halting disease progression. Super lityle decline. Remember the bar is so low that slowdown by 25% can pass trial liow. So far all other competitors' disease modifying drugs failed.

Slowdown by 50% means the HMTM drug patient is declining at half the rate when compared to non-HMTM patients.

Thats why under such environment got profits from long positions safer to lock in some first. You never know when the next mkt selldown will come. My stock trading sifu in jan this yr already said mkt has peaked n started shorting.

https://www.thestar.com.my/business/business-news/2022/06/02/interest-in-genting-spurred-by-progress-in-alzhemier039s-treatment


RHB analyst... OMG!

Sorry but i disagree. Drugs must go thru phase 3 trials before submission to regulators for approval.

If can show a slowdown of abt 25% can pass trial liow. Anything that can slowdown by 50% is a very credible wonder drug. Mind you this is a phase 3 trial. Aduhelm did not even complete their phase 3 trial n FDA approved them. This is so ridiculous!

Posted by cktay > 2 hours ago | Report Abuse

So hopefully, TauRx will be fast-tracked to take over Biogen’s drug.

----------------------------------------------------------------

Biogen's Aduhelm (F.K.N. Aducanumab) is commercially dead. FDA's neuro department is currently under federal investigation for corruptly approving Aduhelm. Huge controversy and fiasco one year ago when FDA gave Biogen "Accelerated Approval" using unproven science of clearing Amyloid deposits as biomarkers.

Biogen and Eisai are putting all their hopes on their next AD drug Lecanumab (BAN2401). Phase 3 result shd be out in 2022 Q4.

Posted by emsvsi > 1 day ago | Report Abuse

Dundee Corp. Class A
https://g.co/kgs/HePp6s
----------------------------------------

They own 4% of TauRx but wrote-off their TauRx investment. Now discover there are diamonds inside their thrash bin. How to buy this Toronto listed stock? The usual brokerage firm that I'm using cannot make it for TSX stocks.

https://www.dundeecorporation.com/holdings/major-investments/default.aspx

Legacy Investments
Company Ownership
Agrimarine 100%
Blue Goose 89.0%
United Hydrocarbon International Corp. 84.0%
Android Industries 20.0%
Tau-Rx 4.0%

Posted by WinSSP > 4 hours ago | Report Abuse

Yes, more peaceful if without fake trader atk long yappings
-------------------------------------------------------------

These are your fakes trades. You kena dementia already? I will keep reminding you. You need help to enroll yourself into Taurx compassionate program? I think they will reject you LoseSSP because you tell a lot of lies here and obviously not compassionate person. Kekeke....



Posted by Stocksafeplayer > Mar 19, 2021 4:25 PM | Report Abuse

Congrats.......
My average is 4.50....Super grateful aldy!!
-----------------------

Posted by Stocksafeplayer > Apr 21, 2021 5:45 PM | Report Abuse

My average is 4.20....4.68 too expensive la
----------------------

Posted by Stocksafeplayer > Sep 1, 2021 4:31 PM | Report Abuse

Average 4.00…. at 5.05… already more than 250k profit on paper… heng ahh!

------------------------

Posted by shareinvestor888 > Jan 27, 2022 6:39 PM | Report Abuse

I bought GenB at 3.50…. Very happy….